Treatment of Malignant Gliomas with a Replicating Adenoviral Vector Expressing Herpes Simplex Virus-Thymidine Kinase

Dharmin Nanda, Ronald Vogels, Menzo Havenga, Cees J. Avezaat, Abraham Bout, and Peter Sillevis Smitt

Department of Neuro-oncology [D. N., P. S. S.]; Daniel den Hoed Cancer Center, University Hospital Rotterdam, 3008 AE Rotterdam; Department of Neurosurgery [C. J. A.], University Hospital Rotterdam, 3015 GD Rotterdam; and Crucell Holland B. V. [R. V., M. H., A. B.], 2301 CA Leiden, the Netherlands

ABSTRACT

We evaluated the interaction between oncolytic, replication-competent adenoviral vectors and the herpes simplex virus-1 thymidine kinase (HSV1-1) gene/ganciclovir (GCV) suicide system for the treatment of malignant gliomas. We constructed a panel of replication-competent adenoviral vectors in which the luciferase (IG.AdSE1α.E3Luc) or HSV1-1 gene (IG.AdSE1α.E3TK) replace the M, 19,000 glycoprotein (gp19K) coding sequence in the E3 region. IG.AdSE1. IG.Ad5.S.clipLuc and IG.AdAppt.TK are E1-deleted viruses that contain the luciferase or the HSV1-1 gene in the former E1 region driven by the human cytomegalovirus promoter. IG.Ad5.Sarcoma 1800HSA.E3Luc contains an irrelevant gene in the E1 region, whereas the gp19K coding sequence in the E3 region is replaced by the luciferase gene as in the replicating virus IG.AdSE1α.E3Luc. For in vitro experiments, we used a panel of human glioma cell lines (U87 MG, T98G, A172, LW5, and U251), a rat gliosarcoma cell line (9 L), and human lung (A549) and prostate carcinoma (P3) cell lines. In vitro, GCV sensitivity (10 μg/ml) was studied in U87 MG cells after infection at a multiplicity of infection of 1 and 10. A s.c. U87 MG glioma xenograft model was established in NIH-nu-nid mice. Tumors of 100–150 mm³ were treated with a single injection of adenovirus 10⁹ IU suspended in 100 μl of PBS, and GCV 100 mg/kg was administered i.p. twice daily for 7 days. The cytotoxic effect of all three replication-competent adenoviral vectors was similar to the cytotoxic effect of wild-type adenovirus 5 on all human cell lines tested, indicating that deletion of the E3 gp19K sequences did not affect the oncolytic effect of the vectors. In vitro, luciferase expression was the same for both E1-deleted vectors (IG.Ad5.S.clipLuc and IG.Ad5.Sarcoma 1800HSA.E3Luc), demonstrating the strength of the internal E3 promoter even in the absence of E1A. However, in vitro expression levels obtained with replication-competent IG.AdSE1α.E3Luc were 3 log higher (allowing infection with a 2–3-log lower multiplicity of infection) in the human cell lines. In U87 MG glioma cells, the oncolytic effect of replication-competent IG.AdSE1α.E3TK was significantly enhanced by the addition of GCV and greatly exceeded the cytotoxicity of replication-incompetent IG.AdAppt.TK combined with GCV. In established s.c. U87 MG glioma xenografts, a single injection of IG.AdSE1α.E3TK resulted in a significant slowing of tumor growth and prolonged survival compared with injection of IG.AdAppt.TK. Addition of GCV slowed tumor growth, further adding to survival. In conclusion, the oncolytic effect of replicating adenoviral vectors and HSV1-1k/GCV have potent antitumor effects in gliomas. When combined, these two approaches are complementary, resulting in a significantly improved treatment outcome. In addition, replication-competent adenoviral vectors missing the E3 gp19K coding sequences, have oncolytic efficacy comparable with wild type. In combination with high expression levels obtained with the natural E3 promoter, such vectors are promising new anticancer agents.

INTRODUCTION

The incidence of primary brain tumors in the Western world is 9–10/100,000 persons and 7/100,000 die of brain tumors each year (1, 2). In children, brain tumors constitute a quarter of all cancer deaths, second only after leukemia (3). In adults, malignant gliomas are the most common primary brain tumors, and despite advances in neurosurgical techniques, radiation treatment, and chemotherapy, the prognosis of these tumors remains dismal, with a median survival of <1 year; and <5% survive for 5 years or more (4–6). Limitations of surgery, radiotherapy, and chemotherapy make the development of new treatment strategies necessary (7). Despite the fact that individual tumor cells spread through the brain at great distances from the primary site (8, 9), ~80% of malignant gliomas recur within a 2-cm margin of the contrast-enhancing rim on computed tomography (10, 11). This high rate of local recurrence within the region of the original tumor, combined with the very low incidence of distant metastases, warrants the additional pursuit of locoregional treatment strategies including gene therapy.

Gene therapy for brain tumors has demonstrated efficacy in a variety of animal models using many different vector systems, including retrovirus (12), adenovirus (13) adeno-associated virus (14), herpes virus (15), and reovirus vectors (16).

Despite promising results in experimental studies, clinical gene therapy trials in brain tumor patients have generally been disappointing. A Phase III study of adjuvant gene therapy in 248 patients with glioblastoma multiforme could not demonstrate any benefit of the injection of HSV-1tk2 retrovirus vector-producing cells (17). A much smaller, Phase I study of adenov. tk injection into malignant gliomas demonstrated that the approach was safe but not very effective (18). A small, uncontrolled trial of HSV-1tk gene therapy in malignant gliomas demonstrated better efficiency of replication-deficient adenovirus vector compared with a retrovirus vector (19).

Better efficacy is crucial for adenoviral cancer gene therapy to become clinically relevant. Most of the adenoviruses used in the clinical studies thus far carry a deletion in the E1 region which renders the virus replication defective or helper-dependent. The efficacy of adenoviral vectors could be greatly increased by using replication-competent vectors (20). The theoretical advantages for the use of replication-competent recombinant adenovirus vector are: (a) the cytolytic effect on infected cells; (b) the subsequent spread of virus to neighboring cells, resulting in additional tumor/tissue penetration; (c) an enhanced immune response; and (d) higher levels of expression of the therapeutic gene are achieved as a result of the replication of adenovirus DNA.

For safety reasons, all replication competent adenoviral vectors are conditionally replicating, usually by small deletions in the E1A or E1B gene. These modifications may, however, decrease efficiency of viral replication, whereas, in the past, intratumoral injection of wild-type adenoviruses has not led to unwanted effects (21). To enhance further the tumoricidal effect of the replication-competent vectors and to provide a “fail-safe” in case of replication outside the tumor, we left E1 intact and placed the HSV1-1k suicide gene in E3 under control of the natural E3 promoter. We then examined the antitumor efficacy of replication-competent vectors.

1 Supported in part by European Union Biomed Grant PL96-1436.

2 To whom requests for reprints should be addressed, at Department of Neurooncology, Daniel den Hoed Cancer Center, University Hospital Rotterdam, P. O. Box 5201, 3008 AE Rotterdam, the Netherlands. E-mail: sillevis@neuh.azr.nl.
the nonconditional replication-competent adenoviral vectors in a panel of glioma cell lines and in an animal model. We could demonstrate a direct lytic effect of the vectors in human cell lines and in vivo that was enhanced further by the suicide HSV1-tk/GCV system.

MATERIALS AND METHODS

Cell Lines

The human glioma cell lines U87 MG, T98G, and A172 were obtained from the American Type Culture Collection (Manassas, VA). The LWS and U251 human glioma cell lines were obtained from Dr. Laneve (Department of Pharmacology, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam; Ref. 13). The A549 human lung carcinoma cell line was purchased from Biowhittaker (Brussels, Belgium; Ref. 13). The PC3, a human prostate cell line (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13). The 9L-rat gliosarcoma brain tumor was a gift from Dr. Hebeda (Department of Experimental Neurosurgery, Free University Hospital Amsterdam, Amsterdam, the Netherlands; Ref. 13).
In Vitro Replication

To assess replication, we determined the CPE in cultured cell lines after infection with the various vectors. Cells were plated in 6-well plates at a density of 10^5 cells/well. Twenty-four h after plating, the cells were infected with the vectors at m.o.i. of 0, 0.1, 1, or 10. The number of days from infection to full CPE or 100% cell death was scored. As positive controls for replication, we used the constitutively Ad5 E1-expressing cell line 293 (28) and wtAd5.

In a separate experiment, we tested the potential of HSV1-tk in combination with GCV as a "fail-safe" for adenoviral replication. A549 cells were seeded in 24-well plates at a density of 10^5 cells/well. Twenty-four h after plating, the cells were incubated with IG.Ad5E1.E3TK or IG.Ad5SE1.E3. E3− for 2 h at m.o.i. of 0, 0.1, or 1. Cells were treated immediately with GCV (Roche, Middrecht, Netherlands) or PBS. The medium was refreshed every day, and GCV was kept at a concentration of 10 μg/ml. CPE was scored daily, and cell viability was assessed quantitatively at days 2, 3, 5, 6, and 8 using the XTT-assay following the manufacturer’s instructions (Sigma Chemical Co., St. Louis, MO).

In Vitro Luciferase Expression

Cells were plated in 6-well plates at a density of 10^5 cells/well. After 24 h, the cells were infected with the vectors at a m.o.i. of 0.01, 0.05, 0.1, 0.5, 1, 5, 10, 50, or 100. Forty-eight h after infection, the cells were harvested using Trypsin-EDTA (Life Technologies, Inc.). The cells were washed twice with PBS (Life Technologies, Inc.). After the last wash, the cells were resuspended in 100 μl Reporter lysis buffer (Promega, Madison, WI). After centrifugation at 14,000 rpm for 5 min, the luciferase activity was measured in the supernatant. The protein content of the supernatant was measured, and the luciferase activity was expressed as relative light units/μg of protein. All experiments were performed in triplicate.

In Vitro GCV Sensitivity

U87 MG cells were plated in 6-well plates at a density of 10^5 cells/well. After 24 h, the cells were infected with the replication-competent and - incompetent vectors carrying the HSV1-tk transgene at m.o.i. of 1 and 10. Forty-eight h after infection, the cells were treated with GCV (Roche) or PBS for 7 days. Day 0 is the start of treatment with GCV or PBS. The medium was refreshed every day, and GCV was kept at a concentration of 10 μg/ml. At days 3–6, the living cells were counted using trypan blue exclusion (29). To calculate the percentage of living cells, we divided the number of cells in the experimental wells by the number of cells in the control wells (no vector, no GCV; 100%). All experiments were performed in triplicate.

Animal Experiments

All experimental protocols were approved by the Institutional Animal Care and Use Committee, in compliance with the Guide for the Care and Use of Laboratory Animals, University Hospital and Erasmus University Rotterdam, The Netherlands. Female Hsd:NIH-bg-nu-xid mice 5–6 weeks of age were purchased (Ref. 30; Harlan Sprague Dawley, Inc., Oxon, England). Mice were housed 3–4/cage and allowed access to food and water ad libitum. After 1 week, 10^7 U87 MG cells were inoculated s.c. into both flanks in 500 μl of HBSS (Life Technologies, Inc.). Animals were treated with a single intratumoral injection of adenovirus 10^9 IU suspended in 100 μl of PBS or 100 μl of PBS alone as a control. GCV 100 mg/kg (or PBS) was administered i.p. twice daily for 7 days beginning 48 h after vector inoculation. The animals were killed by isoflurane when their tumors reached a volume of >4000 mm^3 or after 60 days. Each treatment group consisted of a minimum of three animals (six tumors).

Statistical Analysis

Data were analyzed using GraphPad Prism version 3.0 software (GraphPad Software, Inc., San Diego, CA, 1999). The CPE induced by replication-competent IG.Ad5SE1.E3Luc and IG.Ad5SE1.E3TK and wtAd5 in the human cell lines were compared and analyzed by repeated-measures ANOVA, and posttest analysis was performed using Dunn’s multiple comparison test.

RESULTS

Replication of E1+ Adenoviral Vectors. Full CPE was scored on a variety of cell lines (Table 1). Application of all vectors containing the wild-type E1 sequences resulted in full CPE at m.o.i. of 1 and 10. This indicates that deletion of the gptgK coding sequences in the E3 region had not affected the oncolytic effect of the vectors. As expected, no CPE occurred on the nonpermissive rat gliosarcoma 9L cell line. On 293 cells, all vectors, replication competent and deficient, gave full CPE within 2 days after infection. The efficacy of replication of the E1-containing vectors is similar to wtAd5, as measured by the time after infection to full CPE at m.o.i. 1 and partial CPE at m.o.i. 10 (ANOVA; P = 0.19) and m.o.i. 10 (ANOVA; P = 0.49). The duration to full CPE seems to be dose dependent (ANOVA; P < 0.002). In the posttest analysis, only infection with IG.Ad5SE1.E3Luc resulted in significantly shorter time to CPE at m.o.i. 10 than at m.o.i. 1 (P < 0.05). The shorter time to CPE after infection with IG.Ad5SE1.E3TK and wtAd5 at m.o.i. 10 versus 1 did not reach statistical significance (P > 0.05). The time to full CPE differed largely between cell lines. This may indicate more efficient infection or replication in certain cell lines.

In the fail-safe experiment, the A549 cells that were treated with GCV, immediately after infection with IG.Ad5SE1.E3TK remained 96 (m.o.i., 0.1) to 98% (m.o.i., 1) viable whereas the cells treated with PBS were only 10 (m.o.i., 1; full CPE) to 38% (partial CPE) viable at day 8 (Fig. 2). The A549 cells infected with the replicating empty control vector IG.Ad5SE1.E3− had significantly reduced viability at day 8 (full CPE at m.o.i. 1 and partial CPE at m.o.i. 0.1) irrespective
of treatment with GCV; Fig. 2). These results show that GCV can inhibit the replication and subsequent spread of IG.Ad5E1^-E3TK, and that the inhibition of adenoviral replication by GCV is HSV1-tk-dependent.

**In Vitro Luciferase Expression.** Luciferase expression using the E1^-E3Luc replication-competent vector was compared with two non-replicating vectors containing the luciferase transgene in either E1 (driven by a modified CMV-promoter) or in E3 (driven by the E3 promoter, as in the replication-competent vector). The two nonreplicating vectors gave similar luciferase expression levels in most cell lines, indicating that the internal E3-promoter is of comparable strength with the modified CMV-promoter (Fig. 3). However, at the same m.o.i., the replication-competent vector yielded luciferase expression levels that were ~3 log higher than with both nonreplicating vectors in all human glioma cell lines tested (U87 MG, T98G, A172, and LW5). Alternatively, to obtain a similar expression level, 2–3 log

---

Fig. 2. Replication of adenovirus vectors containing the HSV1-tk gene is effectively blocked by GCV. A549 cells were infected at a m.o.i. of 0.1 and 1 with the replication-competent vectors IG.Ad5E1^-E3TK or IG.Ad5E1^. The cells infected with IG.Ad5E1^-E3TK and immediately treated with GCV remain almost 100% viable. Cells transfected with IG.Ad5E1^-E3TK and subsequently treated with PBS and the cells infected with IG.Ad5E1^ (and then either GCV or PBS) are significantly less viable.

Fig. 3. Forty-eight h after infection, the luciferase expression was measured in the human glioma cell lines U87 MG, T98G, LW5, and A172; the human lung cancer cell line A549; and the nonpermissive rat glioma cell line 9L. Expression levels with the replication-competent vector IG.Ad5E1^-E3Luc are in the permissive cell lines 3 log higher than with the replication-incompetent vectors. The expression levels obtained with nonreplicating IG5.ClipLuc (luciferase in E1 driven by a modified CMV promoter) and IG5.Sarcoma 1800HSA.E3Luc (luciferase in E3 driven by the internal E3 promoter) are comparable with each other in most cell lines. □, IG5.ClipLuc; □, IG5.S1800HSA.E3Luc; □, IG5.E1^-E3Luc.
DISCUSSION

To improve the efficacy of E1-deleted adenoviral vectors, we constructed several replication-competent adenoviral vectors carrying both E1A and E1B sequences and the HSV1-tk suicide gene. The HSV1-tk and luciferase genes replaced the coding sequence of the E3 region gp19K that binds to class I MHC in the endoplasmic reticulum, preventing antigen presentation on the cell surface (32). The transgenes were placed under control of the natural E3 promoter, because less IU of the replication-competent versus the nonreplicating vectors could be used. The A549 cell line showed the same pattern as the human glioma cell line. In the nonpermissive rat 9L cell line, expression levels with the replication-competent vector were ∼1 log higher than with the nonreplicating vectors, indicating that some low-level replication may occur.

In Vitro GCV Sensitivity of U87 MG Cells. Results of GCV sensitivity of U87 MG cells, after infection with m.o.i. 10 and 1, are summarized in Fig. 4. The addition of GCV at a concentration of 10 μg/ml in the absence of adenoviral vectors was not cytotoxic to U87 MG cells (data not shown). Infection with nonreplicating control vector IG.AdApt.TK and then the addition of PBS caused no significant cytotoxicity on days 2–6 at both m.o.i. (P > 0.1). However, infection with replication-competent IG.Ad5E1+.E3TK and then PBS resulted in a significant reduction of the percentage of surviving cells compared with IG.AdApt.TK at day 6 [m.o.i. of 1, P = 0.04 (Fig. 4A); m.o.i. of 10, P < 0.0001 (Fig. 4B)]. Addition of GCV further increased the cytotoxicity of IG.Ad5E1+.E3TK. After infection with IG.Ad5E1+.E3TK at a m.o.i. of 1, the percentage of surviving cells subsequent to GCV treatment was significantly lower than after PBS, on both day 2 (P = 0.0002) and day 6 (P < 0.0001; Fig. 4A). After infection with the replicating vector at m.o.i. 10, the number of surviving cells was significantly lower with GCV than with PBS on day 2 (P = 0.004), whereas no surviving cells remained on day 6 in both groups (Fig. 4B).

We then compared the percentage of surviving cells after infection with either the replication-incompetent or replicating HSV1-tk-containing vectors in combination with GCV administration. After infection with m.o.i. 1, the percentage of surviving cells was significantly lower with the replication-competent IG.Ad5E1+.E3TK compared with the nonreplicating vector at both day 2 (P = 0.04) and day 6 (P = 0.0002; Fig. 4A). After infection with m.o.i. 10, the percentage of surviving cells was already low in both groups at day 2 (P = 0.3), and at day 6, no cells had survived either treatment (Fig. 4B).

In Vivo Treatment of U87 MG Xenografts in bg-nu-xid Mice. Treatment results of s.c. U87 MG xenografts in bg-nu-xid mice are summarized in Fig. 5 and Table 2, A–C. The growth curve of tumors treated with PBS and then i.p. PBS was identical to the growth curve of tumors treated with IG.AdApt.TK and then PBS. Compared with these control curves, the intratumoral injection of replication-competent IG.Ad5E1+.E3TK gave slowing of tumor growth, resulting in significantly reduced tumor size at days 6, 11, 18, and 27 (Table 2A and Fig. 5). The oncolytic effect of IG.Ad5E1+.E3TK was strongly enhanced by the administration of GCV, resulting in additional slowing of tumor growth and smaller tumor size at days 6, 11, 18, and 27 (Table 2B and Fig. 5). Compared with the combination treatment of IG.AdApt.TK and then GCV, replication-competent IG.Ad5E1+.E3TK and then GCV was significantly more effective (Table 2C and Fig. 5).

Survival curves demonstrate prolonged survival of mice treated with IG.Ad5E1+.E3TK in combination with GCV (Fig. 6).
Table 2. U87MG xenograft tumor growth after adenoviral vector treatment
Nude mice carrying s.c. U87MG glioma xenografts were treated with a single injection of 10⁹ IU adenoviral vector or PBS and then by either GCV or PBS (days 2–9). Administration of replication-competent IG.Ad5E1+E3TK and then PBS results in significant reduction in tumor growth, indicating a direct oncolytic effect of the vector (A). Administration of GCV significantly enhances the growth suppression by the replication-competent vector (B). The replication-competent vector is more effective than the nonreplicating vector in combination with GCV. Tumor volumes (mm³) are expressed as mean ± SE, and each treatment group was composed of at least six tumors.

<table>
<thead>
<tr>
<th>Day</th>
<th>PBS/PBS</th>
<th>IG.Ad5E1+E3TK/PBS</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>85.3 ± 10.2</td>
<td>85.3 ± 10.2</td>
<td>1.0</td>
</tr>
<tr>
<td>6</td>
<td>198.3 ± 51.3</td>
<td>381.9 ± 160.0</td>
<td>0.3</td>
</tr>
<tr>
<td>11</td>
<td>381.6 ± 69.2</td>
<td>204.2 ± 28.7</td>
<td>0.04</td>
</tr>
<tr>
<td>18</td>
<td>723.8 ± 130.0</td>
<td>403.4 ± 71.1</td>
<td>0.05</td>
</tr>
<tr>
<td>27</td>
<td>4299 ± 635.0</td>
<td>2495 ± 517.4</td>
<td>0.05</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day</th>
<th>IG.Ad5E1+E3TK/PBS</th>
<th>IG.Ad5E1+E3TK/GCV</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>85.3 ± 10.2</td>
<td>62.5 ± 0.6</td>
<td>0.2</td>
</tr>
<tr>
<td>6</td>
<td>381.9 ± 160.0</td>
<td>12.8 ± 4.9</td>
<td>0.002</td>
</tr>
<tr>
<td>11</td>
<td>204.2 ± 28.7</td>
<td>1.3 ± 0.8</td>
<td>0.002</td>
</tr>
<tr>
<td>18</td>
<td>403.1 ± 71.1</td>
<td>0.03 ± 0.02</td>
<td>0.002</td>
</tr>
<tr>
<td>27</td>
<td>2495 ± 517.4</td>
<td>124.7 ± 77.7</td>
<td>0.002</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Day</th>
<th>IG.AdApt.TK/GCV</th>
<th>IG.Ad5E1+E3TK/GCV</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>85.4 ± 12.7</td>
<td>62.5 ± 0.6</td>
<td>0.2</td>
</tr>
<tr>
<td>6</td>
<td>217.0 ± 61.1</td>
<td>12.8 ± 4.9</td>
<td>0.002</td>
</tr>
<tr>
<td>11</td>
<td>223.0 ± 78.2</td>
<td>1.3 ± 0.8</td>
<td>0.002</td>
</tr>
<tr>
<td>18</td>
<td>345.7 ± 181.9</td>
<td>0.03 ± 0.02</td>
<td>0.002</td>
</tr>
<tr>
<td>27</td>
<td>855.3 ± 385.7</td>
<td>124.7 ± 77.7</td>
<td>0.06</td>
</tr>
<tr>
<td>31</td>
<td>2547 ± 689.1</td>
<td>614.2 ± 314.9</td>
<td>0.06</td>
</tr>
</tbody>
</table>

Apart from the direct oncolytic effect on tumor cells (38), replication-competent vectors may enhance further the antitumor efficacy by increased expression levels of a tumoricidal transgene. To test this hypothesis, we examined the antitumor efficacy of E1+ and E1-deleted vectors carrying the HSV1-tk suicide gene. In vitro, the E1+ HSV1-tk vector demonstrated cytotoxicity to the U87 MG glioma cell line that was greatly enhanced by the addition of GCV. The latter combination was also significantly more toxic than infection with the E1-deleted HSV1-tk control vector and then GCV. In vivo, a single injection of the replicative E1+ HSV1-tk vector in established s.c. U87 MG xenografts resulted in a significant slowing of tumor growth. The addition of GCV resulted in additional slowing of tumor growth and significantly prolonged survival. Also, the E1+ HSV1-tk vector in combination with GCV was significantly more effective than the E1-deleted HSV1-tk vector with GCV.

Replication-competent adenoviral vectors are a new and rapidly evolving platform for gene therapy (39). In the past, intratumoral injection of wild-type adenoviruses has not led to unwanted effects (21). However, “virotherapy” for cancer was abandoned because of only a few documented responses and because of the advent of more effective chemotherapeutic agents (20). Bischoff et al. (38) reintroduced the oncolytic effect of adenoviruses with vectors carrying mutations in the early region of the encoding E1B-M₅ 55,000. These vectors only replicate in cells with a deficient p53 pathway and cause specific cytolysis after intratumoral and i.v. administration (40). Subsequently, an additive effect of HSV1-tk/GCV and radiotherapy to the oncolytic effect of E1B-deleted vectors was demonstrated (41, 42). The use of conditional replicating vectors that contain deletions in E1B (or E1A) carries the risk of reduced replication as compared with wtAd5. The present study demonstrates that even vectors replicating as well as wtAd5 don’t cause tumor eradication in some models. Therefore, addition of a therapeutic transgene is probably mandatory, and genes with improved bystander and cytotoxic effects may add heterologous promoters were found to be silent when inserted in this area (33–35). To examine the transgene expression levels obtained from the internal E3 promoter, we also constructed an E1-deleted vector carrying the luciferase gene in E3. The luciferase expression obtained with this construct was similar to a first-generation, E1-deleted adenoviral vector carrying the HSV1-tk vector in established s.c. U87 MG xenografts resulting in a significant slowing of tumor growth. The addition of GCV resulted in additional slowing of tumor growth and significantly prolonged survival. Also, the E1+ HSV1-tk vector in combination with GCV was significantly more effective than the E1-deleted HSV1-tk vector with GCV.

Another concern was the potential disruption of the adenovirus death protein (E3–11.6K) by our cloning strategy. Adenovirus death protein is produced in large amounts at the late stage of infection and is required for effective cell lysis and virus release (36). However, the oncolytic effect of the gp19K-deleted, replicating vectors was similar to wtAd5, as measured by the time after infection to full CPE. The time to full CPE with both wtAd5 and the replication-competent vectors differed largely between the tested cell lines. The time to CPE seemed not to correlate with the level of luciferase expression, indicating that the efficacy of replication may not only depend on the efficacy of cell entry. Elucidating mechanisms affecting the efficiency of adenoviral replication in different cell lines requires additional study to enhance replication potentially (37). As expected, the replication-competent vectors and wtAd5 did not cause CPE in the nonpermissive 9L rat gliosarcoma cell line.

We then compared the luciferase expression levels of the E1+ luciferase vector with both E1-deleted vectors and found that luciferase expression was ≈3 logs higher with the E1+ vector in all permissive (human) cell lines tested. Similar expression levels were obtained with ≈2 log lower m.o.i. of the E1+ vector. Interestingly, infection of the nonpermissive 9L cell line with the E1+ vector resulted in significantly higher luciferase expression than with the E1-deleted vectors. This may indicate either low-level replication of the E1+ vector in the rodent cell line or transactivation of the E3 promoter by E1 proteins.

Fig. 6. Kaplan-Meier survival analysis of nude mice with s.c. U87 MG xenografts. To establish s.c. tumors, mice were inoculated s.c. in both flanks with U87 MG cells (10⁷) in 500 μl of HBSS. The tumor growth was assessed by measuring bidimensional diameters, and when the tumor reached a volume of 100–150 mm³, animals were assigned randomly to a single intratumoral injection with 10⁸ IU of replication-competent IG.Ad5E1+ E3TK, 10⁸ IU of nonreplicating IG.AdApt.TK or PBS. GCV 100 mg/kg (or PBS) was administered i.p. twice daily for 7 days beginning 48 h after vector inoculation. The animals were killed by isoflurane when the tumors reached a volume of >4000 mm³ or after 60 days. Animals treated with replication-competent IG.Ad5E1+ E3TK and GCV lived significantly longer than animals treated with IG.Ad5E1+ E3TK alone or with nonreplicating IG.AdApt.TK combined with GCV.
further to the efficacy of replicating vectors (43). The toxic genes, such as the HSV1-tk gene, can also function as a fail-safe mechanism when replication outside the tumor occurs (41). Here, we demonstrated that adeno viral replication and subsequent spread can be effectively blocked by the immediate administration of GCV. The complex interactions between viral replication and GCV require additional in vivo studies to determine the optimal interval between vector injection and first GCV administration. In clinical studies, conditional replication will be required for patient- and biosafety. An alternative for selective replication is to drive the E1B or/and E1A genes by a tissue or tumor-specific promoter. Such vectors may replicate in target tissue (and tumor) even better than wtAd5. Examples include the use of enhancer/promoter sequences of the prostate specific antigen gene to drive E1A in prostate cancer (44), the fgreg promoter in hepatocellular carcinoma (45), and the DF3/MUC1 promoter in breast cancer (46).

In the present study, we have demonstrated that the addition of the HSV1-tk/GCV suicide system enhances the tumoricidal efficacy of replicating competent adeno viral vectors in glioma cell lines and after intratumoral injection in a glioma xenograft model. The use of a suicide gene has the additional advantage of fail-safe in case of spread of the vector outside the tumor. Safety will be increased further by conditional replication, for instance by using a gfa2 promoter such as the gfa2 promoter, to drive the E1A gene (47).

ACKNOWLEDGMENTS

We gratefully acknowledge Eric Brouwer for technical assistance.

REFERENCES


